Giant cell arteritis (GCA) is a common systemic vasculitis with an unknown etiology. It mainly affects people older than 50 years of age and often presents with symptoms such as headache, jaw claudication, visual loss, polymyalgia rheumatica and increased erythrocyte sedimentation rate (ESR). Established blindness is irreversible if the steroid treatment is not administered within a few days. Here, we report a case of GCA in a patient with a normal ESR whose left eye perceived just light at the initiation of treatment. Immediately prior to the combined treatment with high dose oral steroids and cyclophosphamide, the ESR level had increased to 80 mm/h and the vision improved after the combined treatment four months later
The literature suggests high-dose steroids have a protective effect in preserving vision in giant ce...
Giant cell arteritis (GCA) is a challenging condition to manage. Patients presenting with ION warran...
OBJECTIVES Giant cell arteritis (GCA) may lead to vision loss. To what extent tocilizumab (TCZ) i...
Giant cell arteritis (GCA) is a common systemic vasculitis with an unknown etiology. It mainly affec...
Giant cell arteritis (GCA) is a common systemic vasculitis with an unknown etiology. It mainly affec...
Giant Cell Arteritis (GCA) is a systemic vasculitis of unknown etiology affecting medium and large c...
Giant cell arteritis (GCA) is the most common vasculitis in adults and blindness is a common complic...
To determine the incidence and factors that lead to visual loss after treatment has been started for...
GCA may cause rapid. irreversible visual loss. and is a true neuro-ophthalmic emergency. Although th...
Giant cell arteritis (GCA) is the most common form of vasculitis in individuals aged 50 years and ov...
Background: Visual loss is a recognized complication of giant cell arteritis (GCA); however, its rat...
Aims—To determine if patients with giant cell arteritis (GCA) treated with cortico-steroids develop ...
BACKGROUND: We present the largest study of the frequency and nature of visual complications in a co...
Giant cell arteritis, or also known as temporal arteritis is one of the rheumatological condition th...
Principles: Report on two patients with visual loss due to inflammatory anterior ischaemic optic neu...
The literature suggests high-dose steroids have a protective effect in preserving vision in giant ce...
Giant cell arteritis (GCA) is a challenging condition to manage. Patients presenting with ION warran...
OBJECTIVES Giant cell arteritis (GCA) may lead to vision loss. To what extent tocilizumab (TCZ) i...
Giant cell arteritis (GCA) is a common systemic vasculitis with an unknown etiology. It mainly affec...
Giant cell arteritis (GCA) is a common systemic vasculitis with an unknown etiology. It mainly affec...
Giant Cell Arteritis (GCA) is a systemic vasculitis of unknown etiology affecting medium and large c...
Giant cell arteritis (GCA) is the most common vasculitis in adults and blindness is a common complic...
To determine the incidence and factors that lead to visual loss after treatment has been started for...
GCA may cause rapid. irreversible visual loss. and is a true neuro-ophthalmic emergency. Although th...
Giant cell arteritis (GCA) is the most common form of vasculitis in individuals aged 50 years and ov...
Background: Visual loss is a recognized complication of giant cell arteritis (GCA); however, its rat...
Aims—To determine if patients with giant cell arteritis (GCA) treated with cortico-steroids develop ...
BACKGROUND: We present the largest study of the frequency and nature of visual complications in a co...
Giant cell arteritis, or also known as temporal arteritis is one of the rheumatological condition th...
Principles: Report on two patients with visual loss due to inflammatory anterior ischaemic optic neu...
The literature suggests high-dose steroids have a protective effect in preserving vision in giant ce...
Giant cell arteritis (GCA) is a challenging condition to manage. Patients presenting with ION warran...
OBJECTIVES Giant cell arteritis (GCA) may lead to vision loss. To what extent tocilizumab (TCZ) i...